WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida provides company update and reports fourth quarter and FY 2015 results
Category: Business
Research and Markets: Global Dry Eye Syndrome Market 2015-2019 with Alcon, Allergan, Otsuka Holdings & Santen Pharmaceuticals Dominating
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/kj2mjh/global_dry_eye) has announced the addition of the “Global Dry Eye Syndrome Market 2015-2019” report to their offering. The global dry eye syndrome market i…
Ophthotech Corporation to Present at the Morgan Stanley Global Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Morgan Stanley Global Healthcare Conference.
Research and Markets: 2015 Adaptive Optics Market by Component, End-User and Geography – Global Forecast to 2020 – Military & Defense Sector was the Largest Contributor
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/3vhsjc/adaptive_optics) has announced the addition of the “Adaptive Optics Market by Component, End-User and Geography – Global Forecast to 2020” report to their offering. The global adaptive optics market is expected to reach USD 7,666.4 Million by 2020, at a CAGR of 99.4% between 2015 and 2020 The military & defense sector was the largest contributor to the overall adaptive optics market, accounting
Aerie Pharmaceuticals and Ramot at Tel Aviv University Enter Research Collaboration
IRVINE, Calif. & TEL AVIV, Israel–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and Ramot at Tel Aviv University Ltd., Tel Aviv University’s technology transfer company, today announced a research collaboration and license agreement for a preclinical anti-beta amyloid small molecu
Research and Markets: Optical Coherence Tomography for Healthcare and Life Science: Technology and Market Trends
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/x3v2cr/optical_coherence) has announced the addition of the “Optical Coherence Tomography for Healthcare and Life Science: Technology and Market Trends” report to…
Síndrome de ojo seco: el simposio internacional de Dompé se centra en una nueva investigación para pacientes con necesidades no cubiertas
BARCELONA, España–(BUSINESS WIRE)–Rojez, irritación, picor, ardor o la sensación de tener algo bajo el párpado son los síntomas más comunes del síndrome de ojo seco, un problema cada vez más común asociado a factores relacionados con el entorno, los hábitos y el estilo de vida que llevan a una reducción de la lubricación ocular. El síndrome de ojo seco se subestima a menudo, pero puede tener consecuencias graves en la vista de los pacientes, sobre todo en su variante moderada y grave. Este se
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
Dry eye syndroom: een internationaal symposium van Dompé richt zich op nieuw onderzoek voor aanpak van onvervulde behoeften van patiënten
BARCELONA, Spanje–(BUSINESS WIRE)–Roodheid en irritatie, jeuk en verbranding van het oog en de sensatie van het hebben van een vreemde stof onder het ooglid zijn de meest voorkomende symptomen van het dry eye syndroom, een steeds vaker voorkomend probleem in verband met milieu-, gedrags- en leefstijlfactoren die leiden tot verminderde oculaire smering. Dry eye syndroom wordt vaak onderschat, maar kan aanzienlijke gevolgen hebben voor het gezichtsvermogen van patiënten, vooral in de matige en
Syndrome de l’œil sec : un symposium international organisé par Dompé se consacre aux nouvelles études répondant aux besoins non satisfaits des patients
BARCELONE, Espagne–(BUSINESS WIRE)–Yeux rouges et irrités, démangeaisons et brûlure, ainsi que la sensation d’avoir un corps étranger sous la paupière sont les symptômes les plus courants du syndrome de l’œil sec, un problème de plus en plus commun lié à des facteurs environnementaux, à des comportements et à des modes de vie et qui entraîne une diminution de la lubrification oculaire. Le syndrome de l’œil sec est souvent sous-estimé, mais il peut avoir des répercussions significatives sur la
Trockenes Auge: Ein internationales Symposium von Dompé konzentriert sich auf neue Forschung zu ungedeckten Patientenbedürfnissen
BARCELONA, Spanien–(BUSINESS WIRE)–Rötungen und Reizungen sowie Jucken und Brennen des Auges und das Gefühl, einen Fremdkörper unter dem Augenlid zu haben, sind die häufigsten Symptome des Trockenen Auges, ein immer häufiger auftretendes Problem, das mit Umwelt-, Verhaltens- und Lebensstilfaktoren verbunden ist, die zu einer verminderten Augenschmierung führen. Das Trockene Auge wird häufig unterschätzt, kann jedoch erhebliche Auswirkungen auf das Sehvermögen der Patienten haben, insbesondere
Dry Eye disease: an international symposium by Dompé focuses on new research addressing unmet patient needs
BARCELONA, Spain–(BUSINESS WIRE)–Eye redness and irritation, itchiness and burning of the eye and the sensation of having a foreign body under the eyelid are the most common symptoms of Dry Eye disease, an increasingly common problem associated with environmental, behavioural and lifestyle factors which lead to decreased ocular lubrication. Dry Eye disease is frequently underestimated but can have significant repercussions on patients’ eyesight, especially in its moderate and severe forms. Th
Sindrome dell’occhio secco: un Simposio Internazionale promosso da Dompé sulle nuove prospettive in ricerca per i bisogni non soddisfatti dei pazienti
BARCELLONA, Spagna–(BUSINESS WIRE)–Arrossamento e irritazione agli occhi, prurito e bruciore, vista annebbiata, sensazione di un corpo estraneo nella palpebra. Sono solo alcuni dei più comuni sintomi che caratterizzano la sindrome dell’occhio secco, una condizione sempre più diffusa a causa di fattori ambientali ma anche per comportamenti e stili di vita che portano a trascurare l’importanza di una corretta lubrificazione oculare. La patologia, spesso sottovalutata ma che può avere ripercussi
Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics has been awarded the honor of iPSC industry influencer by BioInformant, a leading research firm serving the stem cell sector. Dr. Lanza was honored both for his specific involvement in early-stage, pioneering research in the area of induced Pluripotent Stem Cells, or “iPSCs”, as we
pSivida CEO Invited to Speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual Symposium
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO invited to speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual symposium in Scottsdale September 21-23
Resumen: Salutaris Medical Devices obtiene la autorización 510(k)
BARCELONA, España–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD®) ha anunciado en el Ophthalmology Futures European Forum 2015 que su fuente braquiterápica y de radionúclidos SMD Sr90-1 ha recibido la autorización 510(k) de la Administración de Alimentos y Medicamentos de EE. UU. La SMD Sr90-1 RBS está indicada para la braquiterapia episcleral de tumores y crecimientos benignos y diseñada para usarse con sistemas de aplicación de braquiterapia manuales. Laurence Marsteller, CEO de Sa
Samenvatting: Salutaris Medical Devices krijgt 510(k)-vergunning
BARCELONA, Spanje–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD ®) heeft op het Ophthalmology Futures European Forum 2015 bekendgemaakt dat zijn SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) een 510(k)-autorisatie heeft gekregen van de Amerikaanse Food and Drug Administration (FDA). De SMD Sr90-1 RBS is bedoeld voor inwendige episclerale bestraling van tumoren of goedaardige groei. Het dient te worden toegepast in een handmatig bestuurbaar systeem voor inwendige bestraling. Laur
ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that its Board of Directors has appointed Steve Davis as President and Chief Executive Officer. Mr. Davis has been serving as ACADIA’s Interim Chief Executive Officer since March 2015. Mr. Davis has also been appointed to the ACADIA Board of
Bruker Introduces Four Next-Generation Preclinical Imaging Systems at WMIC 2015
HONOLULU–(BUSINESS WIRE)–Bruker (NASDAQ: BRKR) today introduced four important new preclinical imaging systems at the World Molecular Imaging Congress 2015 (WMIC, www.wmis.org) in Honolulu, Hawaii. The novel products launched at WMIC each deliver improved performance and convenience for routine imaging, and open new horizons for advanced translational research, while Bruker’s platform philosophy facilitates multimodal imaging projects. Researchers will gain a more complete picture and deeper
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. NUPLAZID is an SSIA (selective sero